1. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
   Rowa Y. Alhabbab, 2020, Front. Genet. CrossRef
2. A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
   Moein Dehbashi et al, 2021, Front. Oncol. CrossRef
3. Cellular based treatment modalities for unresectable hepatocellular carcinoma
   Konstantinos Damiris et al, 2021, WJCO CrossRef
4. CAR-NK Cells in the Treatment of Solid Tumors.
   Ewa Wrona et al, 2021, Int J Mol Sci CrossRef
5. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
   Faroogh Marofi et al, 2021, Front. Oncol. CrossRef
6. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
   Nicolas Jacquelot et al, 2021, IJMS CrossRef
7. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review)
   Worawat Songjang et al, 2021, Biomed Rep CrossRef
8. Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review
   Mina Hosseini et al, 2021, Expert Opinion on Biological Therapy CrossRef
9. Engineered NK Cells Against Cancer and Their Potential Applications Beyond
   Maria Karvouni et al, 2022, Front. Immunol. CrossRef
10. Opportunities and challenges of targeting c-Met in the treatment of digestive tumors
    Zhengchao Zhang et al, 2022, Front. Oncol. CrossRef
11. Adoptive Cell Transfer for Solid Tumors
    Farbod Ghobadinezhad et al, 2023 CrossRef
12. Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
    Pengxiao Su et al, 2023, Front. Oncol. CrossRef
13. A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
    Alain E. Andrea et al, 2024, Front. Immunol. CrossRef